ONVO vs. TRAW, PULM, NXTC, CARA, COCP, TENX, XCUR, ATHA, GOVX, and MIRA
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Traws Pharma (TRAW), Pulmatrix (PULM), NextCure (NXTC), Cara Therapeutics (CARA), Cocrystal Pharma (COCP), Tenax Therapeutics (TENX), Exicure (XCUR), Athira Pharma (ATHA), GeoVax Labs (GOVX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.
Organovo vs.
Traws Pharma (NASDAQ:TRAW) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
In the previous week, Traws Pharma and Traws Pharma both had 1 articles in the media. Traws Pharma's average media sentiment score of 0.59 beat Organovo's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.
Organovo has a net margin of -12,176.70% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of 0.00% beat Organovo's return on equity.
Traws Pharma has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.
7.9% of Traws Pharma shares are owned by institutional investors. Comparatively, 8.2% of Organovo shares are owned by institutional investors. 16.1% of Traws Pharma shares are owned by insiders. Comparatively, 3.7% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Organovo has lower revenue, but higher earnings than Traws Pharma. Organovo is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.
Organovo received 196 more outperform votes than Traws Pharma when rated by MarketBeat users.
Summary
Traws Pharma beats Organovo on 7 of the 13 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organovo Competitors List
Related Companies and Tools
This page (NASDAQ:ONVO) was last updated on 1/21/2025 by MarketBeat.com Staff
